AstraZeneca Says Vaccine 100% Effective Against Severe COVID: ‘No Increased Risk’ of Blood Clots

AstraZeneca’s coronavirus vaccine candidate has shown 79% efficacy against symptomatic disease and 100% efficacy against severe illness and hospitalization, the drugmaker announced Monday.

In phase 3 of the company’s clinical trial, AstraZeneca said the vaccine “was well-tolerated” and that an independent safety board “identified no safety concerns.”

The vaccine, developed with Oxford University, set off alarm bells in recent weeks amid concerns that it may cause blood clotting, but the safety board found “no increased risk of thrombosis or events characterized by thrombosis” among the nearly 22,000 participants who received at least one dose of the vaccine.

AstraZeneca said it will use the data to apply to the Food and Drug Administration for emergency authorization of the vaccine in the U.S. Additionally, AstraZeneca said it will submit its discovery to a scientific journal for peer review.

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Adblock Detected

Please consider supporting us by disabling your ad blocker